









Markets
/
Stocks
/
nasdaq-teva
/

Teva Pharmaceutical Industries Ltd

TEVA

20.460USD

-0.060-0.29%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

23.47BMarket Cap

LossP/E TTM



Teva Pharmaceutical Industries Ltd

20.460

-0.060-0.29%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Teva Pharmaceutical Industries Ltd

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Teva Pharmaceutical Industries Ltd's Score

Industry at a Glance

Industry Ranking

34 / 159

Overall Ranking

98 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

24.376

Target Price

+18.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Teva Pharmaceutical Industries Ltd Highlights

StrengthsRisks

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Undervalued

The company’s latest PE is -145.38, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 734.66M shares, decreasing 10.19% quarter-over-quarter.

Held by Larry Robbins

Star Investor Larry Robbins holds 15.82M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.16, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.18B, representing a year-over-year increase of 0.29%, while its net profit experienced a year-over-year increase of 133.33%.

Score

Industry at a Glance

Previous score

8.16

Change



Financials

5.67

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.85

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.59

Key Metrics

Free cash flow

No Data

Teva Pharmaceutical Industries Ltd's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 5.79, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -145.38, which is -97.56% below the recent high of -3.55 and -0.29% above the recent low of -145.81.

Score

Industry at a Glance

Previous score

5.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.36, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Teva Pharmaceutical Industries Ltd is 25.00, with a high of 29.00 and a low of 18.07.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

24.376

Target Price

+18.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Teva Pharmaceutical Industries Ltd

TEVA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 9.26, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 21.29 and the support level at 19.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.24

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

62.979

Neutral

STOCH(KDJ)(9,3,3)

80.196

Neutral

ATR(14)

0.533

High Vlolatility

CCI(14)

101.407

Buy

Williams %R

20.438

Buy

TRIX(12,20)

0.112

Sell

StochRSI(14)

78.509

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

20.344

Buy

MA10

19.805

Buy

MA20

19.780

Buy

MA50

19.362

Buy

MA100

18.064

Buy

MA200

17.287

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 64.04%, representing a quarter-over-quarter decrease of 1.94%. The largest institutional shareholder is Stanley Druckenmiller, holding a total of 15.97M shares, representing 1.39% of shares outstanding, with 75.44% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Menora Mivtachim Insurance Ltd.

57.40M

+49.10%

Fidelity Management & Research Company LLC

50.63M

-32.76%

Phoenix Investment and Finances Ltd

37.76M

+37.49%

Ion Asset Management Israel Ltd

38.35M

-1.76%

Harel Insurance Investments and Financial Services Ltd

33.39M

+51.39%

BlackRock Institutional Trust Company, N.A.

33.89M

+2.52%

Migdal Insurance and Financial Holdings Ltd

28.69M

+8.92%

Clal Insurance Enterprises Holdings Ltd.

32.36M

-14.37%

Lingotto Investment Management LLP

28.16M

+1.09%

Rubric Capital Management LP

26.00M

+1.76%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 8.70, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.